Voyager Therapeutics (VYGR)

• Market cap: $277M
• 1 day: 0.20%
• 5 days: -5.06%
• 1 month: -18.88%
• 3 months: -36.70%
• 6 months: -41.92%
• Year to date: -15.08%
• 1 year: -30.55%
• 5 years: -63.23%
• 10 years: -71.44%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 162

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

6% more call options, than puts

Call options by funds: $272K | Put options by funds: $256K

1% more funds holding

Funds holding: 127 [Q2] → 128 (+1) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 37

6.61% less ownership

Funds ownership: 71.53% [Q2] → 64.92% (-6.61%) [Q3]

33% less capital invested

Capital invested by funds: $308M [Q2] → $207M (-$100M) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5.73 13% upside
• Avg. target: $15.43 204% upside
• High target: $30 492% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Pete Stavropoulos 9% 1-year accuracy 2 / 22 met price target	13% upside $5.73	Overweight Initiated	10 Jan 2025
Citigroup Samantha Semenkow 20% 1-year accuracy 3 / 15 met price target	137% upside $12	Buy Initiated	2 Dec 2024
Canaccord Genuity Sumant Kulkarni 22% 1-year accuracy 7 / 32 met price target	176% upside $14	Buy Maintained	14 Nov 2024
HC Wainwright & Co. Patrick Trucchio 27% 1-year accuracy 42 / 156 met price target	492% upside $30	Buy Reiterated	14 Nov 2024